Rapamycin and its analogs, rapalogs (33), cause partial responses in about 10% of RCC patients, and have been reported to have major benefit in occasional cases of bladder cancer and other cancer types with TSC1/TSC2 mutations (13). Here, TSC2 is linked to urinary bladder carcinoma.